Failure to Diagnose Lung Cancer Lawyer New York

How Lung Cancer Is Diagnosed

Lung cancer diagnosis involves screening, imaging, biopsy, and pathology:

• Low-dose CT (LDCT) screening: The standard for lung cancer screening in high-risk patients (adults 50-80 with a 20 pack-year smoking history who currently smoke or quit within 15 years). LDCT can detect lung nodules years before they cause symptoms, when the cancer is most treatable.
• Chest X-ray: Often the first imaging study when a patient presents with symptoms (cough, weight loss, hemoptysis). X-rays can detect lung masses but are less sensitive than CT for small nodules. [Link to: /radiology-errors/x-ray-malpractice]
• Chest CT with contrast: The standard for evaluating lung nodules and masses detected on X-ray or screening CT. CT provides detailed images of the size, shape, and characteristics of nodules, helping to distinguish benign from malignant.
• PET scan (FDG-PET): Used to determine whether a nodule is metabolically active (suggesting cancer) and to detect spread to lymph nodes or distant organs (staging).
• Bronchoscopy with biopsy: A pulmonologist uses a flexible scope to examine the airways and obtain tissue samples from visible tumors or guided by ultrasound (EBUS).
• CT-guided needle biopsy: A radiologist uses CT guidance to place a needle into a lung nodule and obtain a tissue sample. [Link to: /radiology-errors/interventional-radiology]
• Surgical biopsy (VATS or thoracotomy): When less invasive methods are inconclusive, a surgeon may perform a video-assisted thoracoscopic surgery (VATS) or open surgical biopsy.
• Pathology and molecular testing: Tissue samples are examined by a pathologist to determine the type of lung cancer (non-small cell, including adenocarcinoma and squamous cell carcinoma; or small cell), the grade, and molecular markers (EGFR, ALK, PD-L1) that guide treatment decisions.
• Sputum cytology: Examination of sputum under a microscope, which can detect cancer cells in some cases.

Common Ways Lung Cancer Is Misdiagnosed

Lung cancer misdiagnosis can occur at any point in the diagnostic process:

• Failure to screen high-risk patients: A primary care physician fails to recommend LDCT screening for a patient who meets the USPSTF criteria (50-80 years old, 20 pack-year smoking history). This allows a preventable cancer to develop undetected.
• Attributing symptoms to a less serious condition: Cough, weight loss, and hemoptysis (coughing up blood) are often attributed to bronchitis, pneumonia, asthma, or smoking-related chronic obstructive pulmonary disease (COPD) without appropriate imaging. A patient with a persistent cough is told it is just bronchitis, without a chest X-ray or CT to rule out cancer.
• Failure to perform imaging: When a patient presents with symptoms concerning for lung cancer (persistent cough, weight loss, hemoptysis, chest pain, recurrent pneumonia), the standard of care requires imaging. Failure to order a chest X-ray or CT may constitute negligence.
• Radiology errors -- missed nodule on CT or X-ray: A lung nodule or mass is visible on the imaging study but is missed by the radiologist. This is the most common type of radiology error in lung cancer cases. [Link to: /radiology-errors/ct-scan-negligence] [Link to: /radiology-errors/x-ray-malpractice]
• Failure to follow up on incidental nodules: A lung nodule is found incidentally on a CT performed for another reason (e.g., cardiac CT, trauma CT), but no follow-up is recommended. The nodule grows and becomes cancer. The standard of care requires that incidental lung nodules be followed according to established guidelines (Fleischner Society guidelines for incidental nodules; Lung-RADS for screening nodules).
• Failure to recommend biopsy: A nodule has suspicious characteristics (size, shape, growth rate) that warrant biopsy, but the physician does not recommend it.
• Biopsy errors: The biopsy misses the tumor (sampling error), or the tissue sample is inadequate for diagnosis. This can lead to a false negative -- the patient is told the nodule is benign when it is actually cancer.
• Pathology errors: The pathologist misinterprets the biopsy tissue -- diagnosing cancer when it is not present (false positive) or missing cancer that is present (false negative). Pathology errors can also involve misclassifying the type or grade of cancer, leading to inappropriate treatment. [Link to: /medical-malpractice/pathology-errors]
• Failure to communicate or follow up: Abnormal results are not communicated to the patient or referring physician, or follow-up appointments are not arranged. The cancer goes untreated. [Link to: /radiology-errors/communication-failures]

Screening and the Standard of Care

The standard of care for lung cancer screening in New York includes:

- LDCT screening for high-risk patients: The U.S. Preventive Services Task Force (USPSTF) recommends annual low-dose CT screening for adults aged 50-80 who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. A pack-year is calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the person has smoked. - Symptomatic patients: Any patient with symptoms concerning for lung cancer (persistent cough, weight loss, hemoptysis, chest pain, recurrent pneumonia, hoarseness, shortness of breath) should undergo imaging -- typically a chest X-ray or CT -- regardless of screening status. - Incidental nodules: Lung nodules found incidentally on imaging performed for other reasons should be followed according to the Fleischner Society guidelines, which provide specific recommendations for follow-up based on nodule size, type (solid, subsolid, ground-glass), and patient risk factors. - Screening nodules: Nodules found on LDCT screening should be managed according to Lung-RADS (Lung Imaging Reporting and Data System), which classifies nodules and provides follow-up recommendations.

Failure to recommend screening for high-risk patients, failure to image symptomatic patients, or failure to follow up on incidental or screening nodules may constitute negligence.

CT and X-Ray Errors in Lung Cancer

Imaging is central to lung cancer diagnosis, and imaging errors are a leading cause of missed diagnosis:

Chest X-ray errors: - Missed lung mass: Lung masses can be missed on chest X-ray, particularly if they are small, in certain locations (apices, behind the heart, behind the clavicles), or obscured by overlapping structures (ribs, clavicles, heart). - Missed nodule: Small nodules may be below the resolution of chest X-ray or may be obscured by other structures. - Failure to compare with prior X-rays: A mass that is new or growing is more concerning than a stable one. Failure to compare with prior studies can lead to missed new findings. - Inadequate views: A chest X-ray should include PA (posteroanterior) and lateral views. If only one view is obtained, findings may be missed. [Link to: /radiology-errors/x-ray-malpractice]

CT scan errors: - Missed nodule: CT is more sensitive than X-ray for detecting lung nodules, but nodules can still be missed -- particularly small nodules, ground-glass nodules, or nodules in certain locations. - Misinterpretation of nodule characteristics: The radiologist must assess the size, shape, margins, and density of nodules to determine the level of suspicion. Misinterpreting a malignant nodule as benign can delay diagnosis. - Failure to use Lung-RADS: Screening CT nodules should be classified using Lung-RADS, which guides follow-up. Failure to use Lung-RADS may lead to inadequate follow-up. - Failure to compare with prior CTs: Growth of a nodule over time is a key indicator of malignancy. Failure to compare with prior CTs can lead to missed growth. [Link to: /radiology-errors/ct-scan-negligence]

The standard of care requires careful image review, comparison with prior studies, appropriate classification of nodules, and prompt communication of suspicious findings. [Link to: /radiology-errors/communication-failures]

Pathology and Biopsy Errors

Pathology and biopsy errors are a less common but devastating cause of lung cancer misdiagnosis:

- False negative biopsy: The biopsy misses the tumor (sampling error) or the tissue sample is inadequate for diagnosis. The patient is told the nodule is benign, and the cancer goes untreated. - False positive biopsy: The pathologist diagnoses cancer when it is not present, leading to unnecessary surgery and treatment. - Misclassification: The pathologist misclassifies the type of lung cancer (non-small cell vs. small cell) or the subtype (adenocarcinoma vs. squamous cell), leading to inappropriate treatment. Molecular markers (EGFR, ALK, PD-L1) must be tested in non-small cell lung cancer to guide targeted therapy and immunotherapy. - Failure to assess molecular markers: Certain genetic markers guide treatment decisions, particularly for advanced lung cancer. Failure to test for these markers may result in inappropriate treatment. - Failure to perform molecular testing: Non-small cell lung cancer should be tested for EGFR mutations, ALK rearrangements, ROS1, and PD-L1 expression, among others. Failure to perform this testing can deny the patient access to targeted therapies.

An independent pathologist should review the slides in any case of suspected pathology error. [Link to: /medical-malpractice/pathology-errors]

When Lung Cancer Misdiagnosis Constitutes Malpractice

Lung cancer misdiagnosis constitutes medical malpractice when a healthcare provider deviated from the accepted standard of care and that deviation caused harm. This includes:

• Failure to screen: A primary care physician failed to recommend LDCT screening for a patient who meets the USPSTF criteria.
• Failure to perform imaging in a symptomatic patient: A patient with persistent cough, weight loss, or hemoptysis was not referred for chest X-ray or CT.
• Misdiagnosis of symptoms: Symptoms were attributed to bronchitis, pneumonia, or COPD without imaging to rule out cancer.
• Radiology errors: A lung nodule or mass was missed on CT or X-ray, or a suspicious nodule was misinterpreted as benign.
• Failure to follow up on incidental nodules: An incidental nodule was found on imaging but was not followed according to Fleischner Society guidelines.
• Biopsy errors: The biopsy missed the tumor (sampling error) or the tissue sample was inadequate.
• Pathology errors: The pathologist missed cancer, misclassified the type, or failed to test for molecular markers.
• Failure to communicate or follow up: Abnormal results were not communicated, or follow-up was not arranged.

The Impact of Delayed Lung Cancer Diagnosis

The impact of a delayed lung cancer diagnosis can be devastating:

- Stage progression: A cancer that could have been diagnosed at stage 1 (5-year survival: 65%) may progress to stage 3 or 4 (5-year survival: 9% for distant metastasis) due to delayed diagnosis. - More aggressive treatment: Later-stage cancer requires more aggressive treatment -- surgery with chemotherapy, radiation, targeted therapy, and immunotherapy. - Spread to lymph nodes and distant organs: Cancer that has spread to lymph nodes or distant organs (brain, bones, liver, adrenal glands) is much harder to treat and significantly reduces survival. - Reduced survival: The most devastating consequence. A patient who could have been cured may face a terminal diagnosis. - Loss of access to targeted therapies: Some targeted therapies and immunotherapies are most effective in early-stage disease. Delayed diagnosis may reduce their effectiveness. - Physical and emotional toll: More aggressive treatment causes more side effects -- nausea, fatigue, neuropathy, hair loss, radiation pneumonitis, and emotional trauma.

The concept of stage migration is central to these cases -- a delay in diagnosis can cause the cancer to progress from one stage to a more advanced stage, dramatically reducing survival chances. [Link to: /misdiagnosis/breast-cancer-misdiagnosis] [Link to: /delayed-diagnosis-lawyer/loss-of-chance]

Lavern's Law and Your Deadline to File

Lung cancer misdiagnosis cases in New York are subject to Lavern's Law, which provides a discovery rule for cancer cases. Under Lavern's Law:

- You have 2.5 years from the date you discovered (or should have discovered) the misdiagnosis to file a lawsuit. - There is an absolute outer limit of 7 years from the date of the negligent act.

This means that even if years have passed since the misdiagnosis, you may still have a valid claim if you discovered the error recently. For example, if you were diagnosed with advanced lung cancer in 2024 and discovered in 2025 that a radiologist missed a nodule on a 2021 CT, you would have 2.5 years from the date of discovery to file.

Lavern's Law applies only to cancer cases. [Link to: /misdiagnosis/laverns-law]

If the misdiagnosis occurred at a municipal hospital (NYC Health + Hospitals), shorter deadlines apply -- 90 days for the notice of claim and 1 year, 90 days for the lawsuit. [Link to: /hospital-negligence/suing-nyc-h-h]

If the misdiagnosis resulted in death, a wrongful death claim under EPTL 5-4.1 must be filed within 2 years of the date of death. [Link to: /wrongful-death-lawyer]

Common Defense Arguments and How We Counter Them

Defense: The patient was a smoker, so the cancer was inevitable.

Defense attorneys use several arguments in lung cancer misdiagnosis cases:

• Our Counter: Smoking is a risk factor for lung cancer, but it does not make cancer inevitable -- and it does not excuse negligence. If the physician failed to screen, failed to image, or failed to follow up on suspicious findings, the delayed diagnosis caused the cancer to progress. The patient may have been a smoker, but they still deserved appropriate medical care. The standard of care applies to all patients, regardless of risk factors.

Defense: The nodule was small and difficult to detect.

Our Counter: The standard of care requires radiologists to detect nodules that a reasonably competent radiologist would detect. We have the CT images independently reviewed by qualified radiology experts who can testify that the nodule was visible and should have been detected. We also examine whether the correct protocol was used and whether the images were of adequate quality. [Link to: /radiology-errors/ct-scan-negligence]

Defense: The delayed diagnosis did not change the outcome.

Our Counter: We use oncologist expert testimony to establish that earlier diagnosis would have changed the outcome -- that the cancer was at a treatable stage when it should have been diagnosed, and that the delay allowed it to progress to a more advanced, less treatable stage. The loss of chance doctrine may also apply, allowing recovery for the reduced chance of survival. [Link to: /delayed-diagnosis-lawyer/loss-of-chance]

Defense: The patient did not follow up on recommended screening.

Our Counter: If the physician recommended screening and the patient did not follow up, the patient may share some responsibility. However, if the physician did not recommend screening, or if abnormal findings were not communicated, the physician may be liable. We examine the medical records to determine what was recommended and communicated. [Link to: /radiology-errors/communication-failures]

Compensation Available in Lung Cancer Misdiagnosis Cases

A successful lung cancer misdiagnosis claim in New York can provide compensation for:

• Medical expenses: Additional surgery, chemotherapy, radiation, targeted therapy, immunotherapy, rehabilitation, ongoing care, and monitoring
• Lost wages and loss of earning capacity
• Pain and suffering: Physical pain, emotional distress, and loss of enjoyment of life (NY has no cap on non-economic damages)
• Permanent disability and disfigurement: From surgery (lobectomy, pneumonectomy), chemotherapy side effects, and metastatic disease
• Loss of chance of survival: The reduced chance of survival caused by the delayed diagnosis
• Wrongful death damages: If the delayed diagnosis caused death [Link to: /wrongful-death-lawyer]

What to Expect Working with MDLaw Firm

When you contact MDLaw Firm about a potential lung cancer misdiagnosis case:

• Free Consultation: We listen to your story and review the basic facts -- at no cost or obligation.
• Immediate Deadline Assessment: We evaluate the Lavern's Law deadline (2.5 years from discovery, 7-year outer limit) and whether a notice of claim is required for municipal facilities.
• Record Retrieval: We obtain all CT scans, X-rays, radiology reports, pathology slides, biopsy results, and medical records.
• Expert Radiology Review: We engage board-certified radiologists to independently review the CT scans and X-rays.
• Expert Pathology Review: We engage independent pathologists to review the biopsy slides.
• Causation Analysis: We use oncologist expert testimony to establish that the delayed diagnosis caused the cancer to progress and reduced survival.
• Litigation: We file within Lavern's Law deadlines and handle all aspects of discovery and trial.
• Resolution: We pursue maximum compensation through settlement or verdict.

Frequently Asked Questions

The value of a medical malpractice case in New York depends on several factors, including the severity of the injury, the strength of liability evidence, and the economic and non-economic damages involved. New York is one of the few states with no caps on medical malpractice damages, meaning there is no artificial limit on what you can recover. Below are typical settlement ranges based on injury severity.